NovoCure (BMV:NVCR N) - Aandelenkoers, Nieuws & Analyse

NVCR N Overzicht aandelen

An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. Meer informatie

NVCR N fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 7.1% per jaar groeien

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 5% per jaar dalen.

Aandelen zijn zeer illiquide

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

NovoCure Limited Concurrenten

MeHow Innovative

SZSE:301363

CN¥12.3b

Qingdao Haier BiomedicalLtd

SHSE:688139

CN¥10.5b

Integra LifeSciences Holdings

NasdaqGS:IART

US$1.8b

Shinva Medical InstrumentLtd

SHSE:600587

CN¥10.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor NovoCure
Historische aandelenkoersen
Huidige aandelenkoers	US$275.39
52 Week Hoogtepunt	US$2,140.47
52 Week Laag	US$275.39
Bèta	0.52
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-86.68%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	NVCR N	MX Medical Equipment	MX Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe NVCR N presteerde ten opzichte van de MX Medical Equipment.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe NVCR N presteerde ten opzichte van de MX markt.

Prijsvolatiliteit

Is NVCR N's price volatile compared to industry and market?
NVCR N volatility
NVCR N Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiele aandelenkoers: NVCR N heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van NVCR N in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2000	1,320	Asaf Danziger	www.novocure.com

NovoCure Limited Samenvatting

Hoe verhouden de winst en inkomsten van NovoCure zich tot de beurswaarde?
NVCR N fundamentele statistieken
Marktkapitalisatie	Mex$27.09b
Inkomsten(TTM)	-Mex$3.35b
Inkomsten(TTM)	Mex$8.56b

3.2x

P/S-verhouding

-8.1x

Koers/Winstverhouding

Is NVCR N overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NVCR N resultatenrekening (TTM)
Inkomsten	US$503.98m
Kosten van inkomsten	US$124.00m
Brutowinst	US$379.98m
Overige uitgaven	US$577.25m
Inkomsten	-US$197.27m

Laatst gerapporteerde inkomsten

Sep 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.85
Brutomarge	75.40%
Nettowinstmarge	-39.14%
Schuld/Eigen Vermogen Verhouding	144.3%

Hoe presteerde NVCR N op de lange termijn?

Bekijk historische prestaties en vergelijking

NVCR N Overzicht aandelen

Beloningen

Risicoanalyse

NovoCure Limited Concurrenten

SZSE:301363

CN¥12.3b

SHSE:688139

CN¥10.5b

NasdaqGS:IART

US$1.8b

SHSE:600587

CN¥10.7b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma

NovoCure Limited Appoints Christoph Brackmann as Senior Financial Advisor

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

Recent updates

Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma

NovoCure Limited Appoints Christoph Brackmann as Senior Financial Advisor

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

Chief Financial Officer recently sold Mex$589k worth of stock

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022)

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Chief Operating Officer recently sold Mex$35m worth of stock

Chief Human Resources Officer recently sold Mex$383k worth of stock

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Insufficient new directors

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Insufficient new directors

Insufficient new directors

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021)

Insufficient new directors

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

Insufficient new directors

Executive Chairman recently sold Mex$1.2m worth of stock

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 2Q 2021)

Insufficient new directors

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Now 20% undervalued after recent price drop

Chief Medical Officer recently sold Mex$5.4m worth of stock

Insufficient new directors

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

General Counsel recently sold Mex$4.6m worth of stock

Insufficient new directors

Novocure Announces Resignation of Todd Longsworth as General Counsel

Insufficient new directors

President recently bought Mex$11m worth of stock

Insufficient new directors

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer